Condition

Stage IV Uveal Melanoma (3)

Iris Melanoma (1)

Medium/Large Size Posterior Uveal Melanoma (1)

Ocular Melanoma With Extraocular Extension (1)

Recurrent Uveal Melanoma (1)

Small Size Posterior Uveal Melanoma (1)

Stage IIIA Uveal Melanoma (1)

Stage IIIB Uveal Melanoma (1)

Stage IIIC Uveal Melanoma (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Terminated (1)

Phase

phase 2 (3)

Sponsor

National Cancer Institute (NCI) (1)

Sidney Kimmel Cancer Center at Thomas Jefferson University (1)

Vanderbilt-Ingram Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

laboratory biomarker analysis (2)

dacarbazine (1)

pembrolizumab (1)

quality-of-life assessment (1)

selumetinib (1)

sir-spheres® (1)

temozolomide (1)

Study Documents

Intervention Type

other (2)

biological (1)

device (1)

drug (1)

Funder Type

Other (2)

NIH (1)

Study Type

Interventional (3)

stage iv uveal melanoma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Stage IV Uveal Melanoma Trial in Philadelphia (Sir-Spheres®)

Active, not recruiting

Stage IV Uveal Melanoma

Sir-Spheres®

Philadelphia, Pennsylvania

Thomas Jefferson University

Dec 20, 2022

Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma Trial in Chicago, Nashville (Pembrolizumab,

Terminated

Has Results

Stage IIIA Uveal Melanoma
+3 more

Pembrolizumab
Laboratory Biomarker Analysis

Chicago, Illinois
+1 more

Sep 3, 2019

Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension Trial in Canada, United

Completed

Has Results

Iris Melanoma
+5 more

Dacarbazine
+4 more

Aurora, Colorado
+32 more

Jun 26, 2017